ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCERDrupad Annapureddy, William C. Huang, Davaro Facundo et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 1
IMPACT OF TUMOR STAGE IN PATIENTS WITH BCG-UNRESPONSIVE NMIBC WHO UNDERGO UPFRONT RADICAL CYSTECTOMY: A LARGE MULTI-INSTITUTIONAL STUDYDrupad Annapureddy, Yair Lotan, Jacob Taylor et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 1
COMPARING EFFICACY OF INTRAVESICAL GEMCITABINE/DOCETAXEL AND BCG IN TREATING VERY HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER AS DEFINED BY THE EUROPEAN ASSOCIATION OF UROLOGY (EAU)Mohamad Abou Chakra, Michael J. O’Donnell, Vignesh T. Packiam et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 0
AN ARTIFICIAL INTELLIGENCE-POWERED MODEL TO PREDICT RESPONSE TO INTRAVESICAL BCG VERSUS GEMCITABINE-DOCETAXEL FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCERVignesh T. Packiam, Michael J. O’Donnell, Ian M. McElree et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 0
IMPROVED OUTCOMES IN BCG-UNRESPONSIVE BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE UNDERGOING BLADDER SPARING THERAPY COMPARED TO T1 DISEASE: RESULTS FROM AN INTERNATIONAL COHORTDrupad Annapureddy, Yair Lotan, Jacob Taylor et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 0